Cytokine Signatures of Immune Checkpoint Inhibitor Myocarditis and the Modifying Role of Clonal Hematopoiesis: A Machine-Learning and Multi-Omics Study
Background Immune checkpoint inhibitor (ICI) myocarditis affects up to 2% of patients on ICI and has up to a 50% mortality. Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a risk factor for ICI myocarditis. Objectives: To leverage a multi-omics approach to evaluate cytokines associated with ICI myocarditis, immunosuppression resistance, CHIP in ICI myocarditis and implicated pathways and cell type contributions. Methods 236 cardio-oncology patients were enrolled, including 88 who were on ICI. Cytokine profiling from patients on ICI were sampled and analyzed using machine learning and explainable artificial intelligence. Single-cell multi-omics of peripheral blood from Yale (n=19), Stanford (n=25), and MGH (n=63) evaluated cell-type contributions of cytokines and implicated pathways. Validation of Yale proteomic analyses was done using the Stanford CYTOF dataset. Results Top features associated with ICI myocarditis included IL13, CXCL10, PDGFA, CCL13, CCL17 and KITlg. Top KEGG pathways associated with ICI myocarditis and immunosuppression resistant ICI myocarditis included JAK STAT signaling, IL17 signaling and lipid/atherosclerosis pathways. At the single-cell level, the consensus signals distinguishing myocarditis from non-myocarditis across cohorts was predominantly driven by module-level JAK STAT, T cell, and Toll like receptor activation. Similar transcription gene programs were activated in CHIP carriers including modules implicated in the pro-inflammatory immune response, such as NF kappa B, IL17, MAPK, and TNF pathways within CHIP cells spanning lymphoid (cytotoxic CD8+ NKT, and natural killer cells) and myeloid lineages. Conclusions Across cohorts, JAK STAT signaling emerges as a convergent and potentially actionable axis in ICI myocarditis that is further amplified in CHIP carriers, supporting cytokine-guided risk stratification and JAK STAT directed immunosuppression as testable strategies.
Authors
- Neal Patrick Smith (ORCID: https://orcid.org/0000-0003-1394-3158)
- Eiman Ibrahim (ORCID: https://orcid.org/0000-0002-7445-6540)
- Jaiveer Singh (ORCID: https://orcid.org/0000-0002-2251-0189)
- Ritujith Jayakrishnan
- Alokkumar Jha (ORCID: https://orcid.org/0000-0002-8024-5854)
- Yunju Im (ORCID: https://orcid.org/0000-0001-7596-3803)
- Ross L. Levine (ORCID: https://orcid.org/0000-0002-7884-1905)
- Carlos Felipe Matute Martinez (ORCID: https://orcid.org/0000-0002-5174-1349)
- Han Zhu (ORCID: https://orcid.org/0000-0002-2751-7814)
- Evaline Cheng (ORCID: https://orcid.org/0000-0003-4137-8926)
- Jennifer M. Kwan (ORCID: https://orcid.org/0000-0002-4715-1848)
- Stephanie Halene (ORCID: https://orcid.org/0000-0002-2737-9810)
- Anastasia Ardasheva (ORCID: https://orcid.org/0000-0001-5525-3564)
- Jennifer VanOudenhove (ORCID: https://orcid.org/0000-0001-8206-5542)
- Nancy Manchanda (ORCID: https://orcid.org/0000-0003-3216-0968)
- Giulia Biancon (ORCID: https://orcid.org/0000-0003-0182-7766)
- John Hwa (ORCID: https://orcid.org/0000-0001-7366-2628)
- Anthos Christofides (ORCID: https://orcid.org/0000-0003-1769-6182)
- Avnith Vijayram
- Dat Hong
- James L Cross
- Rachel Jaber Chehayeb
- Chloe Villani
- Akarvin Jeyashanmugaraja
- Derrick Lin
- Emily Yuan Shuan Lin
Institutions
- Boston University (US)
- Yale New Haven Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Yale Cancer Center (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Stanford Medicine (US)
- Weill Cornell Medicine (US)
- University of Nebraska Medical Center (US)
- Carnegie Mellon University (US)
- University of Missouri (US)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-12
- DOI
- https://doi.org/10.64898/2026.11.11.26367634
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- preprint